Anika Therapeutics (NASDAQ:ANIK) Posts Quarterly Earnings Results, Misses Expectations By $0.13 EPS

Anika Therapeutics (NASDAQ:ANIK) posted its quarterly earnings data on Wednesday. The biotechnology company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.13), Zacks reports. Anika Therapeutics had a negative return on equity of 2.22% and a negative net margin of 59.40%.

Anika Therapeutics Trading Up 1.9 %

NASDAQ:ANIK opened at $17.11 on Thursday. Anika Therapeutics has a 12 month low of $15.40 and a 12 month high of $29.11. The firm has a fifty day simple moving average of $16.92 and a 200-day simple moving average of $19.65. The company has a market capitalization of $250.59 million, a P/E ratio of -2.57 and a beta of 0.95.

Anika Therapeutics Company Profile

Anika Therapeutics, Inc, a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.